A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

    Research output: Contribution to journalArticlepeer-review

    Original languageEnglish
    JournalUnknown Journal
    Publication statusPublished - Dec 2014

    Cite this